Inner Balance review

Inner Balance does two useful things at once: it publishes what its NAD⁺ costs, and it tells you exactly what you are getting — a 200 mg-per-serving prescription sublingual tablet, not a vague longevity drip. The purchase mechanics are what to weigh against that. You take a quiz, you go straight to checkout, and a provider reviews your information afterwards; and the six-month satisfaction guarantee the brand markets heavily does not cover the NAD⁺ at all.

Inner Balance is a women-focused hormone telehealth brand founded by Dr. Sarah Daccarett, MD, and run by Inner Balance, LLC, whose terms are governed by Idaho law. Its catalog is four prescription products: Oestra, a compounded bioidentical estradiol cream that is the flagship; Libida, a sublingual libido tablet formulated with oxytocin; a prescription sublingual NAD⁺ at 200 mg per serving; and BodyMatched, a compounded prescription face cream. Its own product page states "NAD+ 200mg per serving, sublingual for optimal absorption. From $183/mo." It accepts HSA and FSA payment, states that no insurance is needed, and lists cancel-anytime billing and unlimited clinical follow-up with the NAD⁺ plan.

Quiz-first and asynchronous, and the ordering matters more than usual. The brand's own FAQ describes the sequence plainly: "Start by taking our health quiz. If you're a candidate, you'll move straight to checkout. After a board-certified provider reviews your info, your custom prescription is sent to the pharmacy and shipped directly to you." Checkout precedes provider review, but the public FAQ does not establish when the card is charged. Confirm the selected plan debit and what happens if the clinician does not prescribe before submitting payment details. No baseline labs are required to start, which removes friction and also removes a data point. The founder is named and credentialed, which is a genuine advantage over an anonymous brand, and the operating states are not published anywhere; the only coverage claim on the site is that the founder is licensed in 50 states, which is a statement about one clinician rather than about the service. The compounding pharmacy is not named, though it is described as a national 503A pharmacy certified by NABP, LegitScript and PCAB — a description of a partner you cannot look up.

Published, and published for the right molecule: NAD⁺ from $183 a month, stated on the product page rather than gated behind the quiz. Three things qualify it. First, "from" is doing work — the exact plan tiers are only revealed inside the quiz funnel, so the entry figure is not necessarily your figure. Second, NAD⁺ is expressly excluded from the advertised refund guarantee. The six-month and 14-day windows concern Oestra, so they should not be treated as NAD⁺ terms; ask what resolution applies to a NAD⁺ order that cannot be filled. Third, promotional percentages appear on product tiles without a discounted dollar figure published outside the funnel, so the advertised discount is not something you can price in advance. Before ordering, confirm the tier you are actually being placed on, and confirm the NAD⁺-specific cancellation and refund position in writing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The compounding pharmacy is not named — it is described as NABP, LegitScript and PCAB certified, which is a claim about a facility you cannot verify by name, and compounded sterile and non-sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the sublingual route deserves a direct answer because it is the brand's own selling point. "Sublingual for optimal absorption" is an absorption argument, and absorption is not the thing in question. No controlled human trial shows that sublingual, injected or intranasal NAD⁺ produces a clinical outcome; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly. The NAD⁺ forms that have human trial data are the oral precursors NR and NMN, and what those trials demonstrate is that they raise blood NAD⁺ — a raised biomarker, not a demonstrated benefit. Delivering a compound more efficiently does not generate outcome data for it. Separately, the flagship estradiol product is a compounded bioidentical hormone, which is also not an FDA-approved finished product. Individual results vary.